Disclosure of Alzheimer's disease biomarker status in subjects with mild cognitive impairment by Visser, Pieter Jelle et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Disclosure of Alzheimer’s disease biomarker status in subjects with mild
cognitive impairment
Visser, Pieter Jelle; Wolf, Henrike; Frisoni, Giovanni; Gertz, Hermann-Josef
Abstract: Unspecified
DOI: 10.2217/bmm.12.58
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-73933
Published Version
Originally published at:
Visser, Pieter Jelle; Wolf, Henrike; Frisoni, Giovanni; Gertz, Hermann-Josef (2012). Disclosure of
Alzheimer’s disease biomarker status in subjects with mild cognitive impairment. Biomarkers in Medicine,
6(4):365-368. DOI: 10.2217/bmm.12.58
Editorial
365ISSN 1752-036310.2217/BMM.12.58 © 2012 Future Medicine Ltd Biomarkers Med. (2012) 6(4), 365–368
“Future studies … [will] improve the opportunities for an informed choice for 
Alzheimer’s disease biomarker assessment and disclosure of the results.”
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Disclosure of Alzheimer’s disease biomarker status in 
subjects with mild cognitive impairment
Biomarkers for Alzheimer’s disease (AD) 
pathology now give the opportunity to diag-
nose AD in subjects with mild cognitive impair-
ment (MCI). AD biomarker assessment in this 
population is currently not part of routine clini-
cal care, but it is nevertheless performed with 
increasing frequency. This raises several prac-
tical and ethical issues. The disclosure of AD 
biomarker status may have a stronger impact on 
subjects with MCI than on demented subjects. 
In addition, AD biomarker scores may often be 
near the threshold for an abnormal score or may 
be conflicting with other AD biomarker scores 
because of the early disease stage. Moreover, the 
prognosis of MCI subjects with abnormal AD 
biomarkers remains uncertain for individual 
patients. In this editorial, we will comment on 
the interpretation of AD biomarker scores in 
subjects with MCI and present an approach to 
disclose them.
Current diagnostic work-up of 
subjects with MCI
MCI refers to objective cognitive impairment 
that is not severe enough to warrant a diagnosis 
of dementia. The diagnosis is based on a clini-
cal examination including administration of 
rating scales or neuropsychological tests. MCI 
is a syndromal diagnosis that can be caused 
by somatic, psychiatric or neurological condi-
tions. A total of 30–80% of subjects have AD 
as the underlying pathology depending on the 
definition of MCI and the age of the subject [1]. 
The diagnostic work-up of subjects with MCI 
typically consists of blood analysis and com-
puted tomography or MRI in order to identify 
causes of MCI that may be treatable such as 
metabolic or vascular disorders. The majority 
of the patients with MCI are told that they have 
an increased risk for AD, and almost 90% are 
invited for follow-up [2].
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Potential advantages 
& disadvantages of AD biomarker 
testing in subjects with MCI
The obvious advantage of AD biomarker analy-
sis is that subjects can be informed on whether 
AD is the underlying cause of their impairments. 
This may reduce uncertainty compared with the 
situation in which subjects are told that MCI is 
associated with an increased risk for AD but that 
follow-up is needed to determine the outcome. 
Information on AD biomarker status will help 
MCI subjects and their relatives to understand 
the cause of the impairments and to anticipate 
the future [3]. It will also help clinicians to plan 
medical care.
There are also several disadvantages. The 
outcome of MCI subjects with abnormal AD 
biomarkers is uncertain: patients may become 
demented within 1 year or after 10 years [4]. 
There are no therapeutic implications as evi-
dence-based treatment for MCI subjects with 
abnormal AD biomarkers is lacking. Information 
on the presence of AD biomarkers may cause 
stress to patients and the family and may have 
implications for health insurance or work.
Which AD biomarkers are available?
According to the amyloid cascade hypothesis, 
the primary event in AD is abnormal amyloid 
processing, which is then followed by neuronal 
injury. Biomarkers for AD can likewise be sub-
divided into markers for amyloid dysregulation 
and markers for neuronal injury. Research cri-
teria for AD recommend decreased b-amyloid 
(Ab)1–42 in cerebrospinal f luid (CSF) and 
increased binding of PET-amyloid tracers as 
markers of amyloid pathology and increased tau 
in CSF, hippocampal atrophy and hypoperfu-
sion or hypometabolism as measured by PET or 
single-photon emission computed tomography 
imaging as markers for neuronal injury [5,6]. part of
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Interpretation of AD biomarker 
scores
There are several general considerations for 
interpreting biomarker results. First, while AD 
biomarkers relate to AD pathology, our under-
standing of AD pathophysiology is incomplete. 
For example, the type of amyloid aggregation 
may vary and this may be reflected in biomarker 
scores [7]. Areas affected by neurodegeneration 
differ between patients and this also influences 
biomarker scores [8]. Moreover, diagnostic and 
prognostic accuracy vary with the position of 
biomarkers in the amyloid cascade [9]. Amyloid 
markers have a higher sensitivity for the diag-
nosis of AD in subjects with MCI than injury 
markers [4,9,10]. By contrast, injury markers have 
a better prognostic value than amyloid markers 
and can predict time to onset of dementia [9]. 
Finally, it is difficult to provide numeric data for 
prognosis to individual patients. Most studies 
have a follow-up of less than 3 years, and the few 
studies with a long-term follow-up need cross-
validation. Studies on the outcome of borderline 
or conflicting biomarker scores are lacking. 
 n Interpretation of abnormal test 
scores
Abnormal biomarker scores increase the like-
lihood for conversion to AD-type dementia 
within 3 years by a factor of 2–4 [11–14]. After an 
average follow-up of 9 years, approximately 90% 
of the subjects with a combination of abnormal 
Ab1–42 and tau in CSF converted to AD-type 
dementia [4]. We found that 30% of the subjects 
with abnormal CSF Ab1–42 and normal injury 
markers converted to AD-type dementia after 
4 years compared with 80–90% of the subjects 
with abnormal CSF Ab1–42 and one or more 
abnormal injury markers [15].
 n Interpretation of normal test scores
A normal biomarker score reduces the likelihood 
for progression to AD-type dementia within 
3 years by a factor of 2–6 [11–14]. After an aver-
age follow-up of 9 years, however, approximately 
20% of the subjects with a combination of nor-
mal Ab1–42 and tau in CSF at baseline converted 
to AD-type dementia [4]. In another study, 15% 
of the subjects with both normal amyloid and 
injury markers converted to AD-type dementia 
after 5 years [16].
 n Interpretation of test scores near the 
cut-off point
Scores near the cut-off point are common. Our 
own unpublished data showed that 16% of the 
subjects with MCI had a CSF Ab1–42 value 
10% above or below the cut-off point for an 
abnormal score. A borderline score could mean 
that a subject is an early stage of the disease or it 
could result from inaccurate assay performance 
as the coefficient of variance for CSF Ab1–42 or 
tau assays can be as large as 26% [17]. Borderline 
scores should therefore be interpreted together 
with results of other tests, and the coefficient 
of variance  of the laboratory and biomarker or 
cognitive assessment may be repeated in 1 year.
 n Interpretation of conflicting test 
scores
Conflicting test scores are also common. Our 
own unpublished data showed that 60% of the 
subjects with MCI had conflicting scores for CSF 
Ab1–42, CSF tau and hippocampal atrop hy. 
Conflicting amyloid markers could result from 
differences between CSF and PET markers in 
their ability to detect specific types of amyloid 
aggregation [7]. Conflicting injury markers may 
indicate variability in disease expression [9]. 
Abnormal amyloid markers with normal injury 
markers may reflect early-stage AD or non-AD 
causes of MCI such as Lewy body dementia [18]. 
Abnormal injury markers with normal amyloid 
markers may suggest non-AD causes of MCI or 
an atypical presentation of AD. Again, results 
should be interpreted together with results 
of other tests, and biomarker or cognitive 
assessment may be repeated.
Shared decision-making & disclosure
Given the uncertainties presented above and the 
lack of treatment implications, careful counsel-
ing of the patient should be performed before 
and after biomarker testing. As an approach for 
this, we propose the shared decision-making 
(SDM) model. In general, SDM is a process by 
which a healthcare choice is made jointly by the 
doctor and the patient. SDM can be positioned 
as a ‘middle ground’ between paternalism (i.e., 
physicians make the decisions) and informed 
choice (i.e., patients make the decisions) as 
described by Makoul and Clayman [19]. It is 
crucial to give information on possible outcomes 
before biomarker testing, as this will facilitate 
the disclosure of the results. With regards to 
MCI diagnosis, SDM includes the explanation 
of the memory problems by the patient and the 
presentation of diagnostic options by the physi-
cian. Advantages and disadvantages of further 
diagnostic steps should be discussed consider-
ing the fact that doctors and patients may have 
different perspectives on the relative importance 
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and benefits of the assessment. The lack of treat-
ment opportunities with early diagnosis needs to 
be discussed in parti cular. Clear arrangements 
about the sequence of diagnostic tests should be 
made. In agreement with the patient, a decision 
may be deferred to a later time if agreement is 
sought with family members or other profes-
sionals. SDM and disclosure can be applied 
stepwise:
  Initial exploration and clinical examination of 
subject. Discuss:
 − The worry about possible AD and 
dementia, and whether this is the 
information the patients wishes to 
obtain;
 − The diagnostic assessments to be 
performed (history, cognitive testing and 
neurological, psychiatric and physical 
examination).
  Additional diagnostic testing not specific for 
AD. In case cognitive disturbances fit the 
MCI criteria, discuss the performance of 
neuro imaging, blood tests and other tests to 
identify causes of MCI, other than AD.
  Assessment AD biomarkers. In case no other 
causes of MCI are detected, mention the pos-
sibility of performing AD-specific diagnostic 
tests. Discuss: 
 − The risk of AD without biomarker 
assessment;
 − The change in prognosis after AD biomar-
ker assessment (abnormal score: AD likely 
but time to dementia uncertain; normal 
score: AD unlikely, although not excluded);
 − The possibility of contradictory results or 
borderline scores;
 − The lack of treatment implications if tests 
are abnormal;
 − The possible negative effects for 
psychological well-being, health insurance 
or work;
 − The type of tests available and strengths 
and limitations of each test; 
 − The alternative for AD biomarker testing 
(‘wait and see’). 
 The decision to continue the diagnostic 
process is taken together with the patient.
  Disclosure of biomarker results. Discuss impli-
cations of normal, abnormal, borderline or 
conflicting biomarker scores. 
Future studies on borderline and conflicting 
scores and studies with long-term follow-up will 
further facilitate SDM and improve the opportu-
nities for an informed choice for AD biomarker 
assessment and disclosure of the results.
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